Skip to main content
Premium Trial:

Request an Annual Quote

Genmab Achieves Milestone in Collaboration with Roche

NEW YORK, Oct. 27 (GenomeWeb News) - Genmab has reached a second milestone in its ongoing antibody development collaboration with Roche, having reached the proof of concept stage with a human antibody, the companies said today.


The size of the milestone was not disclosed.

The partnership was formed in May 2001, and calls for Genmab to create human antibodies against a variety of disease targets provided by Roche. Genmab stands to receive up to $100 million in milestones, as well as royalties on sales of products resulting from the deal. Genmab may also obtain the right to develop certain products based on disease targets identified by Roche.


The companies said that they now have moved two antibodies into the proof of concept stage of development.

The Scan

Push Toward Approval

The Wall Street Journal reports the US Food and Drug Administration is under pressure to grant full approval to SARS-CoV-2 vaccines.

Deer Exposure

About 40 percent of deer in a handful of US states carry antibodies to SARS-CoV-2, according to Nature News.

Millions But Not Enough

NPR reports the US is set to send 110 million SARS-CoV-2 vaccine doses abroad, but that billions are needed.

PNAS Papers on CRISPR-Edited Cancer Models, Multiple Sclerosis Neuroinflammation, Parasitic Wasps

In PNAS this week: gene-editing approach for developing cancer models, role of extracellular proteins in multiple sclerosis, and more.